Rintatolimod

AIM ImmunoTech initiates development of Ampligen as a vaccine adjuvant for avian influenza, partnering with Amarex Clinical Research for IND application management.

Safety Committee grants approval for Phase 2 portion of AIM ImmunoTech's Phase 1b/2 trial evaluating Ampligen in combination with AstraZeneca's Imfinzi for late-stage pancreatic cancer treatment.

AIM ImmunoTech's AMP-518 study results support Ampligen as a potential therapeutic for moderate-to-severe Post-COVID fatigue.

AIM ImmunoTech highlights the continued development of Ampligen (rintatolimod) across multiple clinical programs targeting pancreatic cancer and Long-COVID.

A phase 1 clinical trial at Roswell Park Comprehensive Cancer Center reveals a promising new treatment for triple-negative breast cancer (TNBC).